Back to search results

PODS Trial: Dexamethasone Dosing After Brain Tumor Surgery

This study, called the PODS Trial, is looking at different ways to give a medicine called dexamethasone after brain tumor surgery (craniotomy). Dexamethasone is a steroid that helps reduce swelling around the brain, but it can also cause side effects like high blood sugar or problems with wound healing. This trial wants to see if a lower, tapering dose of dexamethasone can still effectively reduce swelling while also reducing these side effects. You might be able to join if you are 18 or older and have certain brain tumors like low-grade glioma, malignant brain glioma, malignant brain neoplasm, or meningioma. The study will measure how long you stay in the hospital, if you need to be readmitted within 30 days, and if you need repeat head imaging. This trial plans to enroll 200 participants.

Study design
This is an interventional study where participants are randomly assigned to one of two groups receiving different dosing schedules of dexamethasone. It plans to enroll 200 participants.
What's involved
You would undergo blood sample collection, MRI and CT scans, and complete questionnaires. Dexamethasone would be given on days 1-15.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes up to 3 months after surgery, including repeat imaging and length of hospital stay, and 30-day readmission rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06132685

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Recruiting
PHASE2Ages 18+InterventionalTreatment
Emory University
~200 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyDexamethasoneMagnetic Resonance ImagingQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Length of hospital stay
Measured over Up to 3 months
+2 more outcomes measured

Conditions

Low Grade Glioma
Malignant Brain Glioma
Malignant Brain Neoplasm
Meningioma

Explore related trials

GliomaMeningiomaMetastatic Malignant Neoplasm in the Brain

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Kimberly Hoang, MD · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute

Who to contact

Kimberly Hoang, MD
[email protected]
404-778-5770
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis
Age equal to or above 18

Exclusion

Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction
Tumor causing compression of the sella or pituitary dysfunction
Known immunodeficiency - including but not limited to severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), lymphocytopenia
Taking immunosuppressive drugs - including but not limited to methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab. Greater than two weeks of recent daily corticosteroid use or the use of corticosteroids equivalent to \> 85 mg of dexamethasone in the last month
Current lymphoma or leukemia
History of solid organ transplant
Minors \< 18
Pregnant women
History of cerebrovascular accident leading to neurologic deficit

What this trial measures

  • Length of hospital stayUp to 3 months

    The two-sample t-test or Mann-Whitney U test utilized to estimate the differences between the two groups. General linear model employed in the multivariable analysis to estimate the adjusted difference in length of hospital stay between the two groups after adjusting for other factors.

  • 30-day repeat admission rateAt 30 days after surgery

    Comparison between the two groups assessed using Fisher exact test or Chi-Square test. Logistic regression used to compare between the two groups after adjusting for other factors. Odds ratios (OR) and 95% confidence intervals (CIs) calculated to evaluate the strength of any association.

  • Need for repeat head imagingUp to 3 months

    Comparison between the two groups assessed using Fisher exact test or Chi-Square test. Logistic regression used to compare between the two groups after adjusting for other factors. OR and 95% CIs calculated to evaluate the strength of any association.